FHIR IG analytics| Package | hl7.fhir.uv.ebm |
| Resource Type | Evidence |
| Id | Evidence-236552.json |
| FHIR Version | R6 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: Evidence 236552
version: 66; Last updated: 2025-10-07 17:12:54+0000; Language: en
Profile: ComparativeEvidence
url: https://fevir.net/resources/Evidence/236552
identifier: FEvIR Object Identifier/236552, outcomeId/313880, picoId/85789, sectionId/73212
name: End_stage_kidney_disease_from_MAGICapp_313880
title: MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
citeAs:
MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236552. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236552. Computable resource at: https://fevir.net/resources/Evidence/236552#json.
status: Active
author: Computable Publishing®: MAGIC-to-FEvIR Converter:
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
| Code | Value[x] |
| Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) | ComparativeEvidence |
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
| Type | Target[x] |
| Part Of | MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report) |
description:
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
assertion:
There is no important difference between GLP-1 receptor agonists and standard care.
variableDefinition
description:
Adults with type 2 diabetes with moderate CV risk
variableRole: Population
observed: Adults with type 2 diabetes and established CVD (but no CKD)
variableDefinition
description:
GroupAssignment: GLP-1 RA vs. Standard care
variableRole: Exposure
comparatorCategory: Standard care
variableDefinition
description:
End-stage kidney disease
variableRole: Outcome
observed: End-stage kidney disease
synthesisType: SYSTEMATIC_REVIEW
studyDesign: randomized assignment
statistic
description:
Risk Difference -0.4% (CI95 -0.7% to -0.2%)
statisticType: risk difference
quantity: -0.004
SampleSizes
NumberOfStudies NumberOfParticipants 4 10762 AttributeEstimates
Type Range CI95 -0.007--0.002
statistic
description:
OR 0.78 (CI95 0.67 to 0.92)
statisticType: odds ratio
quantity: 0.78
SampleSizes
NumberOfStudies NumberOfParticipants 4 10762 AttributeEstimates
Type Range CI95 0.67-0.92
certainty
type: Overall certainty
rating: High certainty
Subcomponents
Type Rating Risk of Bias NOTSET Inconsistency NOTSET Indirectness NOTSET Imprecision NOTSET Publication Bias NOTSET
{
"resourceType": "Evidence",
"id": "236552",
"meta": {
"versionId": "66",
"lastUpdated": "2025-10-07T17:12:54.639Z",
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
"language": "en",
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"url": "https://fevir.net/resources/Evidence/236552",
"identifier": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "FEvIR Object Identifier"
},
"system": "https://fevir.net/FOI",
"value": "236552",
"assigner": {
"display": "Computable Publishing LLC"
}
},
{
"type": {
"text": "outcomeId"
},
"system": "https://app.magicapp.org/#/guidelines",
"value": "313880"
},
{
"type": {
"text": "picoId"
},
"system": "https://app.magicapp.org/#/guidelines",
"value": "85789"
},
{
"type": {
"text": "sectionId"
},
"system": "https://app.magicapp.org/#/guidelines",
"value": "73212"
}
],
"name": "End_stage_kidney_disease_from_MAGICapp_313880",
"title": "MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk",
"citeAs": "MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236552. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236552. Computable resource at: https://fevir.net/resources/Evidence/236552#json.",
"status": "active",
"author": [
{
"name": "Computable Publishing®: MAGIC-to-FEvIR Converter"
}
],
"publisher": "Computable Publishing LLC",
"contact": [
{
"telecom": [
{
"system": "email",
"value": "support@computablepublishing.com"
}
]
}
],
"useContext": [
{
"code": {
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "evidence-communication",
"display": "Evidence Communication"
},
"valueCodeableConcept": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "ComparativeEvidence",
"display": "ComparativeEvidence"
}
]
}
}
],
"copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"relatesTo": [
{
"type": "part-of",
"targetReference": {
"type": "Composition",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-conversion-report",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
}
}
],
"description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"assertion": "There is no important difference between GLP-1 receptor agonists and standard care.",
"variableDefinition": [
{
"description": "Adults with type 2 diabetes with moderate CV risk",
"variableRole": "population",
"observed": {
"reference": "Group/236533",
"type": "Group",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-population-group-85390-85789",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Adults with type 2 diabetes and established CVD (but no CKD)"
}
},
{
"description": "GroupAssignment: GLP-1 RA vs. Standard care",
"variableRole": "exposure",
"comparatorCategory": "Standard care",
"observed": {
"reference": "EvidenceVariable/236536",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-group-assignment-85390-85789",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "GroupAssignment: GLP-1 RA vs. Standard care"
}
},
{
"description": "End-stage kidney disease",
"variableRole": "outcome",
"observed": {
"reference": "EvidenceVariable/236551",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313880",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "End-stage kidney disease"
}
}
],
"synthesisType": [
{
"text": "SYSTEMATIC_REVIEW"
}
],
"studyDesign": [
{
"coding": [
{
"system": "http://hl7.org/fhir/study-design",
"code": "SEVCO:01003",
"display": "randomized assignment"
}
]
}
],
"statistic": [
{
"description": "Risk Difference -0.4% (CI95 -0.7% to -0.2%)",
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000424",
"display": "risk difference"
}
]
},
"quantity": {
"value": -0.004
},
"sampleSize": {
"numberOfStudies": 4,
"numberOfParticipants": 10762
},
"attributeEstimate": [
{
"type": {
"text": "CI95"
},
"range": {
"low": {
"value": -0.007
},
"high": {
"value": -0.002
}
}
}
]
},
{
"description": "OR 0.78 (CI95 0.67 to 0.92)",
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000182",
"display": "odds ratio"
}
]
},
"quantity": {
"value": 0.78
},
"sampleSize": {
"numberOfStudies": 4,
"numberOfParticipants": 10762
},
"attributeEstimate": [
{
"type": {
"text": "CI95"
},
"range": {
"low": {
"value": 0.67
},
"high": {
"value": 0.92
}
}
}
]
}
],
"certainty": [
{
"type": {
"coding": [
{
"system": "http://hl7.org/fhir/certainty-type",
"code": "Overall",
"display": "Overall certainty"
}
]
},
"rating": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/27834",
"code": "RJCS-2003",
"display": "High certainty"
}
]
},
"subcomponent": [
{
"type": {
"text": "Risk of Bias"
},
"rating": {
"text": "NOTSET"
}
},
{
"type": {
"text": "Inconsistency"
},
"rating": {
"text": "NOTSET"
}
},
{
"type": {
"text": "Indirectness"
},
"rating": {
"text": "NOTSET"
}
},
{
"type": {
"text": "Imprecision"
},
"rating": {
"text": "NOTSET"
}
},
{
"type": {
"text": "Publication Bias"
},
"rating": {
"text": "NOTSET"
}
}
]
}
]
}